内容简介：
【简介】 The Hong Kong Institute of Biotechnology Ltd. (HKIB) was founded in 1988 with a donation from the Hong Kong Jockey Club Charities Trust by the Council of the Chinese University of Hong Kong (CUHK) as a non-profit making but self-financing downstream development centre for biotechnology products. With grants from the Hong Kong SAR Government’s Industrial Support Fund and the World Health Organization (WHO), HKIB established a pilot-scale manufacturing plant to produce clinical trial material of human vaccines and biopharmaceuticals under global Good Manufacturing Practices (GMP) guidelines. Its first product is an anti-malaria transmission-blocking vaccine TBV25H that enters Phase I human trial under the sponsorship of HKIB’s Clinical Trial Monitoring Unit (CMU). The CMU also offers clinical monitoring services to global companies.
In 1997, HKIB established the Hong Kong Pharmaceutical Technology Centre (HKPTC) that provides technical support services on GMP implementation to local pharmaceutical industry to upgrade its manufacturing processes so that the products can be exported worldwide. HKIB also has a plant biotechnology programme that develops cost-effective micro-propagation processes for products which include traditional Chinese medicines (TCM) and ornamental plants. HKIB’s newly established process development facility for extraction and concentration of TCM will further solidify its pivotal role in the downstream development of health food and pharmaceuticals based on Chinese medicines for the SAR’s manufacturing sector.
The Hong Kong Institute of Biotechnology, Ltd. dedicates itself to providing the catalyst and essential infrastructure for the emergence of a successful biotechnology industry in Hong Kong SAR through downstream R&D support and an incubator facility for local entrepreneurs to develop biotechnology products.
